Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1

Conditions

Neoplasms 17Breast Neoplasms 10Carcinoma, Non-Small-Cell Lung 9Neoplasm Metastasis 6Prostatic Neoplasms 5Melanoma 5Lung Neoplasms 5Solid Tumor 3Pain, Postoperative 3Lymphoma, Non-Hodgkin 3Lymphoma 3Leukemia, Myeloid, Acute 3Gastrointestinal Stromal Tumors 3Colorectal Neoplasms 3Anxiety Disorders 3Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Pain 2Glioma 2Colonic Neoplasms 2Choledocholithiasis 2Choledochal Cyst 2Carcinoma 2Advanced Solid Tumor 2Advanced Malignancies 2cMET-dysregulated Advanced Solid Tumors 1Urothelial Cancer 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1

Interventions

resiniferatoxin 3Ketamine 3Morphine 2Methadone 2Dexmedetomidine 2ziconotide 1substance P-saporin 1Standard of Care 1Sodium Chloride 1Ropivacaine 1Pregabalin 1Passive Cutaneous Anaphylaxis 1Midazolam 1Lidocaine 1Infusion Pumps, Implantable 1Hydromorphone 1Fentanyl 1Calcium Dobesilate 1Acetaminophen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Pain, Intractable × Midazolam × Clear all
NCT01687751 2015-05-25

Pilot Study Comparing Treatment With Dexmedetomidine to Midazolam for Symptom Control in Advanced Cancer Patients

Fraser Health

Phase 2 Withdrawn
Other

Death, Delirium, Dyspnea, Nausea, Neoplasms, Pain, Intractable

Data powered by HemOnc (CC BY 4.0) Colophon âš¡